GE HealthCare Technologies Inc (GEHC)

NASDAQ
Currency in USD
Disclaimer
68.05
+0.12(+0.18%)
Closed
After Hours
68.39+0.34(+0.50%)
Day's Range
67.8668.68
52 wk Range
53.0087.83
Prev. Close
67.93
Open
68.39
Day's Range
67.86-68.68
52 wk Range
53-87.83
Volume
1,541,718
Average Volume (3m)
2,795,585
1-Year Change
-
Shares Outstanding
455,242,974
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
83.04
Upside +22.03%

People Also Watch

74.41
CNC
-0.80%
521.56
IDXX
+0.50%
287.20
PANW
-1.91%
73.44
ON
+1.60%
117.94
DXCM
+0.63%
How do you feel today about GEHC?
Vote to see community's results!
or
  • 3 Key Takeaways From Q1 13F Season

GE HealthCare Technologies Inc Company Profile

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women’s health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women’s health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.